Investigating how gene mutations affect diabetes susceptibility in patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the impact of mutations in susceptibility genes associated with Type 2 Diabetes Mellitus (T2DM) on the expression of these genes in both T2DM patients and healthy controls. Participants will include newly diagnosed T2DM patients and healthy subjects, from whom fresh blood samples and pancreatic tissues will be collected. The study will analyze the expression levels of various T2DM susceptibility genes using techniques such as ELISA, PCR, and immunohistochemistry. Additionally, the research will compare gene expression differences among participants with varying genotypes and assess their relationship with clinical characteristics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. no drug therapy; 25 to 70 years old; Hemoglobin A1c (HbA1c) 7%-12%; BMI 20-35 kg/m2; Stable body weight (≤10% change within 3 months)（For newly diagnosed patients with T2DM）.
2. 25 to 60 years old; BMI 19-26 kg/m2; in good health, with no abnormalities of motor system, digestive system, respiratory system, urogenital system, blood system, circulatory system, nervous/mental system, endocrine system, etc（For healthy subjects）.
3. 20-80 years old; surgical resection of part or all of the pancreas; pancreatic lesions confirmed by enhanced CT or magnetic resonance (MR) examination or confirmed by intraoperative and postoperative pathology（For the patients in general surgical）.

Exclusion Criteria:

1. had taken antidiabetic drugs;
2. had a history of pancreatic surgery;
3. Complicated with severe organ lesions;
4. Long-term use of drugs that affect pancreatic function.

Where it's running

• China, Jiangsu, Department of Endocrinology
  Xuzhou, China Recruiting

Study contacts

• Study coordinator: Tao Wang, Ph.D
• Email: misswt2011@126.com
• Phone: 13815344640

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating genetic factors affecting diabetes treatment response

  This study is trying to see how genetic differences affect how well the diabetes drug exenatide works for Chinese patients with Type 2 Diabetes.

  Recruiting The Affiliated Hospital of Xuzhou Medical University · Xuzhou, China · NCT06256419

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Acupuncture plus vitamin B12 for diabetic heart nerve damage

  This study tests whether adding acupuncture to standard care and vitamin B12 can help adults with type 2 diabetes who have damaged the nerves that control the heart.

  Recruiting The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07907536

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Body composition changes after starting GLP-1 therapies in adults with obesity or type 2 diabetes

  This study will follow adults with obesity and/or type 2 diabetes who are starting or adjusting a GLP-1 receptor agonist to see how their muscle and fat change over about a year.

  Recruiting at 2 sites Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Mexico City, Mexico City and 1 other locations · NCT07835360

• Single-dose PK study of HRS-4729 in adults with and without kidney impairment

  This study tests a single dose of HRS-4729 to see how the body handles it in adults with various levels of kidney function compared with healthy adults.

  Recruiting Phase 1 Fujian Shengdi Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07807059

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.